CN112094321A - His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用 - Google Patents

His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用 Download PDF

Info

Publication number
CN112094321A
CN112094321A CN201910528641.7A CN201910528641A CN112094321A CN 112094321 A CN112094321 A CN 112094321A CN 201910528641 A CN201910528641 A CN 201910528641A CN 112094321 A CN112094321 A CN 112094321A
Authority
CN
China
Prior art keywords
gly
glu
obzl
trt
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910528641.7A
Other languages
English (en)
Other versions
CN112094321B (zh
Inventor
赵明
彭师奇
梁梦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Original Assignee
Capital Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University filed Critical Capital Medical University
Priority to CN201910528641.7A priority Critical patent/CN112094321B/zh
Publication of CN112094321A publication Critical patent/CN112094321A/zh
Application granted granted Critical
Publication of CN112094321B publication Critical patent/CN112094321B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了下面通式的His‑Gly‑Glu修饰的甲氨蝶呤(式中R1为His‑Gly‑Glu时R2为OH,R1为OH时R2为His‑Gly‑Glu,以及R1和R2同时为His‑Gly‑Glu),公开了它们的制备方法,公开了它们对肿瘤转移的抑制作用。因而本发明公开了它们在制备抗肿瘤转移药物中的应用。
Figure DDA0002099014140000011

Description

His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用
技术领域
本发明涉及His-Gly-Glu修饰的甲氨蝶呤,涉及它们的制备方法,涉及它们的抗肿瘤转移作用。因而本发明涉及它们在制备抗肿瘤转移药物中的应用。本发明属于生物医药领域。
背景技术
癌症是指细胞不受控制以及不正常的增殖,并有机会通过机体血液系统或者淋巴系统向其它部位扩散转移的的一类疾病,是世界性的重大医学难关。据国家癌症中心2019年初发布的我国2015年各地区恶性肿瘤发病以及死亡数据结果显示,白血病位列死亡率最高的恶性肿瘤前十位。作为最早用于治疗急性白血病的药物之一,甲氨蝶呤已有70余年临床应用史。可是,骨髓毒性,肝毒性,肾毒性,口腔粘膜副作用以及耐药性严重限制了甲氨蝶呤的应用及疗效。发明人在一份申请书中描述了用His-Gly-Glu修饰甲氨蝶呤得到的下面通式的His-Gly-Glu-甲氨蝶呤(式中R1为His-Gly-Glu时R2为OH,R1为OH时R2为His-Gly-Glu,以及R1和R2同时为His-Gly-Glu)可克服这些问题的发明。本案进一步描述His-Gly-Glu-甲氨蝶呤意外地具有抗肿瘤转移活性。根据这个意外的发现，发明人提出了本发明。
Figure BDA0002099014120000011
发明内容
本发明的第一个内容是提供下面通式的His-Gly-Glu修饰的甲氨蝶呤(式中R1为His-Gly-Glu时R2为OH,R1为OH时R2为His-Gly-Glu,以及R1和R2同时为His-Gly-Glu)。
Figure BDA0002099014120000012
本发明的第二个内容是提供His-Gly-Glu修饰的甲氨蝶呤的制备方法,该方法包括：
1.采用二环己基碳二亚胺为缩合剂,N-羟基苯并三氮唑为催化剂,液相合成Fmoc-His(Trt)-Gly-Glu(OBzl)-OBzl；
2.脱除Fmoc合成His(Trt)-Gly-Glu(OBzl)-OBzl；
3.采用二环己基碳二亚胺为缩合剂,N-羟基苯并三氮唑为催化剂,将甲氨蝶呤与His(Trt)-Gly-Glu(OBzl)-OBzl偶联生成如下通式的His(Trt)-Gly-Glu(OBzl)-OBzl修饰的甲氨蝶呤,式中R1’为His(Trt)-Gly-Glu(OBzl)-OBzl时R2’为OH,R1’为OH时R2’为His(Trt)-Gly-Glu(OBzl)-OBzl,以及R1’和R2’同时为His(Trt)-Gly-Glu(OBzl)-OBzl；
Figure BDA0002099014120000021
4在酸性条件下脱除保护基生成下面通式的His-Gly-Glu修饰的甲氨蝶呤(式中R1为His-Gly-Glu时R2为OH,R1为OH时R2为His-Gly-Glu,以及R1和R2同时为His-Gly-Glu)。
Figure BDA0002099014120000022
本发明的第三个内容是评价上面通式的His-Gly-Glu修饰的甲氨蝶呤的抑制肿瘤转移活性。
附图说明
图1His-Gly-Glu修饰的甲氨蝶呤的合成路线。(ⅰ)无水四氢呋喃,二环己基碳二亚胺,N-羟基苯并三氮唑,N-甲基吗啉；(ⅱ)氯化氢的乙酸乙酯溶液；(ⅲ)20％哌啶的二氯甲烷溶液；(ⅳ)无水N,N-二甲基甲酰胺,二环己基碳二亚胺,N-羟基苯并三氮唑,N-甲基吗啉；(ⅴ)三氟乙酸/三氟甲磺酸。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备Boc-Gly-Glu(OBzl)-OBzl(1)
用60mL无水四氢呋喃溶解1.00g(5.72mmol)Boc-Gly,得到1号溶液。将1.41g(6.84mmol)二环己基碳二亚胺和0.77g(5.71mmol)N-羟基苯并三唑的无水四氢呋喃溶液加入到1号溶液中搅拌30分钟。加入1.90g(5.22mmol)HCl·Glu(OBzl)-OBzl,用N-甲基吗啉调节反应液pH至9,移去冰浴,在室温下充分搅拌19小时后TLC(二氯甲烷/甲醇＝30/1)显示反应完成,终止反应。滤除反应液中的白色固体二环己基脲,浓缩,残留物用100mL乙酸乙酯溶解,溶液依次分别用饱和碳酸氢钠水溶液洗(30mL×3),饱和氯化钠水溶液洗(30mL×3),5％硫酸氢钾水溶液洗(30mL×3)，饱和氯化钠水溶液洗(30mL×3),饱和碳酸氢钠水溶液洗(30mL×3),饱和氯化钠水溶液洗(30mL×3),得到的乙酸乙酯相用无水硫酸钠干燥12小时,过滤,浓缩,得到2.53g(100％)目标化合物,为黄色油状物。ESI-MS(m/e):485[M+H]+。
实施例2制备Gly-Glu(OBzl)-OBzl(2)
将1.12g(2.32mmol)化合物(1)用无水乙酸乙酯溶解。0℃与搅拌下,加入20mL氯化氢的乙酸乙酯溶液(4M),充分搅拌9小时后TLC(二氯甲烷/甲醇＝30/1)显示反应完成。温水浴条件下,反复减压浓缩反应液,随后用无水乙酸乙酯溶解反应物,浓缩(3次),再用无水乙醚反复磨洗反应物,得到0.89g(100％)目标化合物,为黄色粘稠油状物。ESI-MS(m/e):385[M+H]+。
实施例3制备Fmoc-His(Trt)-Gly-Glu(OBzl)-OBzl(3)
采用实施例1的方法,从1.40g(2.26mmol)Fmoc-His(Trt)和0.89g(2.32mmol)化合物(2)中得到1.50g(67％)目标化合物,为无色粉末。ESI-MS(m/e):986[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.44(d,J＝7.5Hz,1H),8.34-8.28(m,1H),7.89(d,J＝7.5Hz,2H),7.68(m,2H),7.36-7.28(m,25H),7.06-7.03(m,6H),6.73(s,1H),5.07(s,2H),5.03(s,2H),4.39-4.38(m,1H),4.28-4.14(m,4H),3.78-3.67(m,2H),2.89-2.73(m,2H),2.43-2.38(m,2H),2.06-2.00(m,1H),1.89-1.80(m,1H)。
实施例4制备His(Trt)-Gly-Glu(OBzl)-OBzl(4)
0℃与搅拌下,用10mL20％哌啶的二氯甲烷溶液溶解0.72g(0.73mmol)化合物(3),搅拌5小时后TLC(二氯甲烷/甲醇＝30/1)显示反应完成,终止反应。在25℃水浴条件下,减压旋除溶剂,得到白色固体,加入石油醚反复磨洗反应物,同样用无水乙醚磨洗3次,经减压硅胶柱层析纯化,得到0.39g(68％)目标化合物,为无色粉末。ESI+MS(m/e):764[M+H]+,1HNMR(300MHz,DMSO-d6):δ/ppm＝8.81(d,J＝8.1Hz,1H),8.20(s,1H),7.37-7.29(m,20H),7.08-7.06(m,6H),6.68(s,1H),5.06(s,2H),5.03(s,2H),4.45-4.44(m,2H),3.73-3.69(m,2H),3.42-3.41(m,1H),2.74-2.67(m,2H),2.42(m,2H),2.03-1.99(m,1H),1.85-1.80(m,1H)。
实施例5制备His(Trt)-Gly-Glu(OBzl)-OBzl修饰的甲氨蝶呤(1a,1b,1c)
用50mL无水N,N-二甲基甲酰胺溶解0.54g(1.19mmol)甲氨蝶呤,得到1号溶液,0℃与搅拌下,将0.29g(1.41mmol)二环己基碳二亚胺和0.17g(1.26mmol)N-羟基苯并三唑的无水N,N-二甲基甲酰胺溶液加入到1号溶液中,搅拌30分钟。加入0.92g(1.21mmol)化合物(4),用N-甲基吗啉调节反应液pH至9,移除冰浴,在室温下充分搅拌8小时后TLC(乙酸乙酯/水/冰醋酸＝6/1/1)显示反应完成,过滤除去不溶白色固体二环己基脲,浓缩,经制备薄层析纯化(乙酸乙酯/水/冰醋酸＝6/1/1)分别得到0.28g(19％)化合物1a,0.45g(38％)化合物1b和0.18g(12％)化合物1c。它们的结构如下：
Figure BDA0002099014120000041
1a为橘黄色粉末,ESI-MS(m/e):1198.86[M+H]-；1H NMR(300MHz,DMSO-d6):δ/ppm＝8.53-8.51(m,1H),8.43(m,1H),8.23(s,1H),8.16-8.13(d,J＝7.8Hz,1H),7.95(s,1H),7.72(m,3H),7.33-7.26(m,21H),7.01-6.95(m,6H),6.85(s,1H),6.68-6.63(m,5H),5.05(s,2H),5.01(s,2H),4.70(s,2H),4.35(m,3H),3.71(m,2H),3.12(s,3H),2.89(m,2H),2.44-2.35(m,2H),2.00-1.53(m,6H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝172.54,172.46,171.81,171.70,171.68,169.55,169.53,163.33,163.15,162.80,155.67,151.26,149.53,149.50,146.40,146.37,142.57,142.50,136.59,136.51,136.59,136.51,136.32,129.70,129.64,129.64,129.54,128.83,128.80,128.60,128.58,128.41,128.37,128.34,128.24,128.19,128.09,128.07,127.99,127.11,121.93,121.66,121.57,111.43,111.28,74.94,66.36,65.89,55.35,55.32,53.90,51.46,51.52,51.48,31.24,30.11,30.01,26.40,25.80。
1b为橘黄色粉末,Q-TOF-MS(m/e):1943[M+H]-；1H NMR(300MHz,DMSO-d6):δ/ppm＝8.63-8.60(m,1H),8.51-8.46(m,2H),8.28-8.25(m,3H),7.96(s,2H),7.68-7.65(m,3H),7.39-7.30(m,39H),7.03-6.98(m,13H),6.73-6.66(m,5H),5.02(s,8H),4.74(s,2H),4.38(m,4H),4.27(m,1H),3.79-3.53(m,2H),3.15(s,3H),2.82-2.73(m,4H),2.38-2.28(m,4H),2.09-1.87(m,8H)；13C NMR(125MHz,DMSO-d6)＝:δ/ppm＝172.72,172.47,172.45,172.41,172.34,172.15,172.01,171.86,171.78,171.76,171.69,169.65,169.55,169.45,163.33,163.17,162.78,157.16,155.68,151.41,151.33,149.50,149.50,146.40,146.36,142.59,138.35,136.55,137.51,137.01,136.55,136.53,136.29,136.28,129.67,129.52,128.86,128.84,128.58,128.51,128.43,128.38,128.33,128.28,128.25,128.15,128.10,127.98,127.10,126.87,121.93,121.44,121.17,119.94,119.44,111.27,75.03,74.97,66.41,66.38,65.91,55.35,54.23,53.69,53.30,51.48,47.97,42.61,33.82,31.24,30.09,30.07,30.00,26.48,16.43,25.80。
1c为橘黄色粉末,ESI-MS(m/e):1198.76[M+H]-；1H NMR(300MHz,DMSO-d6):δ/ppm＝8.56(s,1H),7.63(m,4H),7.36-7.30(m,21H),7.05-7.02(m,6H),6.80(d,J＝7.8Hz,21H),6.69(s,1H),6.62(s,2H),5.05(s,2H),5.02(s,2H),4.76(s,2H),4.37(m,3H),3.99(m,2H),3.18(s,3H),2.89(m,2H),2.39(m,2H),1.80(m,6H)；13C NMR(125MHz,DMSO-d6):δ/ppm＝173.12,172.30,171.93,171.92,169.95,169.83,163.33,163.18,162.78,157.17,155.67,151.17,151.14,149.58,146.45,142.61,136.60,136.35,129.68,128.87,128.82,128.73,128.61,128.48,128.41,128.34,128.22,128.12,128.11,127.98,126.87,122.66,122.58,121.91,119.98,49.06,47.97,42.92,32.60,30.09,26.40,26.35。
实施例6制备结构式如下的His-Gly-Glu修饰甲氨蝶呤α羧基(2a)
Figure BDA0002099014120000051
称取0.14g(0.12mmol)化合物1a,0℃与搅拌下,先缓慢加入1.5mL三氟乙酸,再加入0.5mL三氟甲磺酸,反应40分钟后,终止反应。0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟,随即加入30mL冰乙醚,析出橘黄色不溶物,静置,弃除上清,重复3次。用少量水溶解反应物,再用稀氨水调节溶液pH＝8,经C18柱层析纯化,收集洗脱液。将收集液在-80℃低温预冻,冷冻干燥机冻干样品,得到0.016g(17％)化合物2a,为橘黄色粉末。ESI-MS(m/e):778[M+H]+,1H NMR(300MHz,DMSO-d6):δ/ppm＝8.57(s,1H),8.38(d,J＝6.9Hz,1H),8.27(m,1H),8.22-8.20(m,1H),7.97(d,J＝7.5Hz,1H),7.74(d,J＝8.4Hz,2H),7.45(d,J＝7.5Hz,2H),6.84-6.82(m,3H),6.66(s,1H),4.80(s,2H),4.41-4.26(m,3H),3.85-3.59(m,2H),3.22(s,3H),2.98-2.93(m,2H),2.27-2.19(m,4H),1.98-1.82(m,4H)；13CNMR(125MHz,DMSO-d6:D2O＝10:1):δ/ppm＝176.02,173.07,172.87,171.95,171.74,169.46,168.27,168.11,162.99,161.98,153.74,151.67,149.60,148.05,134.56,131.81,131.42,129.45,121.87,120.54,117.50,111.72,55.04,53.79,53.24,52.92,42.58,42.50,31.17,30.97,27.95,27.35,26.58。
实施例7制备结构式如下的His-Gly-Glu修饰甲氨蝶呤α,γ羧基(2b)
Figure BDA0002099014120000061
称取0.14g(0.12mmol)化合物1b,0℃与搅拌下,先缓慢加入1.5mL三氟乙酸,再加入0.5mL三氟甲磺酸,搅拌40分钟后,终止反应。0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟,随即加入30mL冰乙醚,析出橘黄色不溶物,静置,弃除上清,重复3次。加入5mL水溶解反应物,再用稀氨水调节溶液pH＝8,经C18柱层析纯化,收集洗脱液。将收集液在-80℃低温预冻,冷冻干燥机冻干样品,得到0.014g(11％)化合物2b,为橘黄色粉末。ESI-MS(m/e):1101.87[M+H]+；1H NMR(300MHz,DMSO-d6):δ/ppm＝8.55(s,1H),8.40-8.31(m,4H),8.25(d,J＝6.3Hz,1H),8.10-8.03(m,2H),7.76-7.71(m,4H),7.66(s,1H),7.56(s,1H),0.92(d,J＝8.1Hz,2H),6.83-6.80(m,3H),4.80(s,2H),4.45-4.43(m,1H),4.24(m,4H),3.85-3.51(m,4H),3.22(s,3H),2.94-2.73(m,4H),2.26(m,4H),2.17-2.15(m,2H),1.99-1.95(m,3H),1.83-1.80(m,3H)；13C NMR(75MHz,DMSO-d6):δ/ppm＝174.56,174.47,173.90,173.79,172.49,172.23,172.09,171.73,169.30,169.26,167.13,163.16,163.06,155.20,151.41,149.56,146.68,135.10,129.53,121.92,121.58,119.67,117.74,117.63,111.57,55.38,55.31,53.73,53.39,53.31,51.94,42.72,42.64,32.28,30.73,29.45,29.43,29.30,27.06,27.00。
实施例8制备结构式如下的His-Gly-Glu修饰甲氨蝶呤γ羧基(2c)
Figure BDA0002099014120000062
称取0.10g(0.088mmol)化合物1c,0℃与搅拌下,先缓慢加入1mL三氟乙酸,再缓慢加入0.3mL三氟甲磺酸,反应40分钟后,终止反应。0℃与搅拌下,用循环水式真空泵抽除反应瓶内挥发性酸气30分钟,随即加入30mL冰乙醚,析出橘黄色不溶物,静置,弃除上清,重复3次。用少量水溶解反应物,再用稀氨水调节溶液pH＝8,经C18柱层析纯化,收集洗脱液。将收集液在-80℃低温预冻,冷冻干燥机冻干样品,得到0.010g(15％)化合物2c,为橘黄色粉末。ESI-MS(m/e):776.92[M+H]-；1H NMR(300MHz,DMSO-d6):δ/ppm＝8.56(s,1H),8.27-8.25(m,3H),7.96(m,1H),7.74-7.72(m,3H),7.58-7.56(m,1H),7.48(s,1H),6.82(m,3H),6.68(s,2H),4.79(s,2H),4.42-4.40(m,1H),4.28-4.26(m,2H),3.69-3.64(m,2H),3.21(s,3H),2.91(m,1H),2.83(m,1H),2.26-2.24(m,4H),2.05-1.76(m,4H)；13C NMR(75MHz,DMSO-d6):δ/ppm＝174.38,174.19,173.69,172.23,171.84,169.38,166.73,163.18,163.09,155.27,151.38,149.60,146.66,146.61,135.08,133.30,129.37,121.90,121.73,117.60,111.58,55.33,53.35,52.58,51.69,42.58,42.55,32.39,30.57,29.57,29.53,27.07,26.90。
实验例1测定化合物2a-c的体外抗肿瘤细胞迁移作用
1)化合物2a-c用无胎牛血清培养基配制成所需浓度。
2)肿瘤细胞为A549(人非小细胞肺癌细胞)。
3)将生长状态良好,处于对数生长期的A549细胞按照5×106个/mL的密度使用无血清的培养基接种在Transwell的上室,每室加入100μL,加入化合物2a-c(终浓度分别为2,0.5,1μM)。同时在下室加入600μL含有10％胎牛血清的培养基,将Transwell小室放入24孔培养板中,于37℃的5％二氧化碳培养箱中孵育7小时。用棉签拭去上室的细胞,吸弃下室的培养基,用4％多聚甲醛固定液固定细胞30分钟,弃固定液,用PBS洗2次,用结晶紫染色15分钟,清水洗去浮色,显微镜观察。随机选取6个不同的视野观察细胞并计算迁移数。结果见表1,数据经t检验。可以确认,在IC10浓度下化合物2a-c有效地抑制肿瘤细胞迁移。其中，2a,2b与Arg-Gly-Asp-Ser(RGDS)相比具有差异,表现出更佳的抗肿瘤细胞迁移的活性,2c与20μM浓度下RGDS抑制A549细胞迁移活性无差异。这是本发明的突出的技术效果。
表1化合物2a-c抑制A549细胞迁移活性
Figure BDA0002099014120000071
a)与PBS组相比,P<0.01；b)与PBS组相比,P<0.01,与RGDS组相比,P<0.01；c)与PBS组相比,P<0.01,与RGDS组相比,P<0.05；d)与PBS组相比,P<0.01,与RGDS组相比,P>0.05；n＝6。
实验例2化合物2a-c抑制肿瘤细胞侵袭活性
1)化合物2a-c用无胎牛血清培养基配制成所需浓度。
2)肿瘤细胞为A549(人非小细胞肺癌细胞)。
3)标准型基底膜胶Matrigel用无血清的培养基稀释10倍,37℃沉降12小时,弃上清液。
4)将生长状态良好,处于对数生长期的A549细胞按照1×107个/mL的密度使用无血清的培养基接种在Transwell的上室,每室加入100μL,加入化合物2a-c(终浓度分别为2,0.5,1μM),同时在下室加入600μL含有10％胎牛血清的培养基,将Transwell小室放入24孔培养板中,37℃的5％二氧化碳培养箱中孵育12小时,用棉签拭去上室的细胞,弃下室的培养基,用4％多聚甲醛固定液固定细胞30分钟,弃固定液,用PBS洗2次,用结晶紫染色15分钟，清水洗去浮色,用显微镜观察。随机选取6个不同的视野观察细胞并计算侵袭数。结果见表2,数据经t检验。可以看到,在IC10浓度下化合物2a-c能有效地抑制肿瘤细胞侵袭，2a-c的抗A549细胞侵袭活性与20μM浓度下Arg-Gly-Asp-Ser(RGDS)无显著性差异。这是本发明的突出的技术效果。
表2化合物2a-c抑制A549细胞侵袭活性
Figure BDA0002099014120000081
a)与PBS组相比,P<0.01；b)与PBS组相比,P<0.05；c)与RGDS组相比,P>0.05n＝6。
实验例3化合物2a-c抑制肿瘤肺转移活性
将本化合物2a-c溶于生理盐水。Lewis小鼠肺癌细胞(LLC,购自ATCC)用含有10％FBS和1×105U·L-1青霉素和100mg·L-1链霉素的DMEM培养基培养。每天传代一次,富集细胞。待细胞处于对数生长期且生长状态良好时消化细胞。用生理盐水调整细胞密度至2×107个/mL。
体重为20±2g的近交系C57BL/6雄性小鼠用左手固定,用75％乙醇涂在小鼠右前肢腋窝皮肤处消毒,右手以1mL无菌注射器于消毒皮下处注射肿瘤细胞悬液,每只注射0.2mL,取接种10天生长状态良好的Lewis肺癌荷瘤小鼠,乙醚麻醉后颈椎脱臼处死。用75％乙醇浸泡消毒10min,在超净台上操作剥离瘤体,选择生长良好的肿瘤组织,在无菌培养皿中剪碎,放置于玻璃组织匀浆器中研磨。研磨时按照瘤块重量(g)/生理盐水体积(mL)为1/3的比例加4℃预冷的生理盐水。研磨制得的细胞悬液用200目的尼龙网过滤,收集的细胞用生理盐水调浓度为2×107个/mL。取体重为20±2g的近交系C57BL/6雄性小鼠,左手固定小鼠,用75％乙醇涂在小鼠右前肢腋窝皮肤处消毒,右手以1mL无菌注射器于消毒皮下处注射肿瘤细胞悬液,每只注射0.2mL,接种后10天可以长成绿豆大小的肿瘤。测量肿瘤体积,肿瘤直径为4-6mm的小鼠随机分组。化合物2a-c组小鼠连续腹腔注射给药10天，剂量为0.033μmol/kg/天。以Arg-Gly-Asp-Ser(RGDS,剂量为20μmol/kg/天)作阳性对照。空白组小鼠每日腹腔注射0.2mL/只/天生理盐水。给药第11天称小鼠体重，乙醚麻醉，剖取各组小鼠的肺计算转移的瘤节数。结果见表3,数据经t检验。可以看到,当2a-c的给药剂量降至His-Gly-Glu的1％时,2a(抑制率为80.97％)和2c(抑制率为82.43％)仍表现出与His-Gly-Glu(抑制率为77.64％)和RGDS(抑制率为72.18％)无统计学差异的体内抗肿瘤转移活性,具有良好的体内抗Lewis肺癌向小鼠肺部转移活性,可见本发明化合物2a,2c具有显著的技术效果。而当2b给药剂量降低为0.033μmol/kg/天时,不具有体内抗Lewis肺癌向小鼠肺部转移的活性。
表3化合物2a-c抑制肿瘤肺转移活性
Figure BDA0002099014120000091
a)与生理盐水组相比P<0.01；b)与生理盐水组相比P>0.05；c)与生理盐水组相比P<0.01,与RGDS组相比P>0.05，与His-Gly-Glu组相比P>0.05；n＝11。

Claims (3)

1.如下通式的His-Gly-Glu修饰的甲氨蝶呤,
Figure FDA0002099014110000011
式中R1为His-Gly-Glu时R2为OH,R1为OH时R2为His-Gly-Glu,以及R1和R2同时为His-Gly-Glu。
2.权利要求1的His-Gly-Glu修饰的甲氨蝶呤的制备方法,该方法包括:
2.1 采用二环己基碳二亚胺为缩合剂,N-羟基苯并三唑为催化剂,液相合成Fmoc-His(Trt)-Gly-Glu(OBzl)-OBzl；
2.2 脱除Fmoc合成His(Trt)-Gly-Glu(OBzl)-OBzl；
2.3 采用二环己基碳二亚胺为缩合剂,N-羟基苯并三唑为催化剂,将甲氨蝶呤与His(Trt)-Gly-Glu(OBzl)-OBzl偶联生成如下通式的His(Trt)-Gly-Glu(OBzl)-OBzl修饰的甲氨蝶呤,式中R1’为His(Trt)-Gly-Glu(OBzl)-OBzl时R2’为OH,R1’为OH时R2’为His(Trt)-Gly-Glu(OBzl)-OBzl,以及R1’和R2’同时为His(Trt)-Gly-Glu(OBzl)-OBzl；
Figure FDA0002099014110000012
2.4 在酸性条件下脱除保护基生成权利要求书1的His-Gly-Glu修饰的甲氨蝶呤。
3.权利要求1的His-Gly-Glu修饰的甲氨蝶呤在制备抗肿瘤转移药物中的应用。
CN201910528641.7A 2019-06-18 2019-06-18 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用 Expired - Fee Related CN112094321B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910528641.7A CN112094321B (zh) 2019-06-18 2019-06-18 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910528641.7A CN112094321B (zh) 2019-06-18 2019-06-18 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用

Publications (2)

Publication Number Publication Date
CN112094321A true CN112094321A (zh) 2020-12-18
CN112094321B CN112094321B (zh) 2022-04-22

Family

ID=73749223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910528641.7A Expired - Fee Related CN112094321B (zh) 2019-06-18 2019-06-18 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用

Country Status (1)

Country Link
CN (1) CN112094321B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094320A (zh) * 2019-06-18 2020-12-18 首都医科大学 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899088A (zh) * 2009-05-26 2010-12-01 首都医科大学 饱和脂肪链酸His-Gly-AA三肽酰胺及其合成方法和应用
CN104211761A (zh) * 2013-06-05 2014-12-17 首都医科大学 饱和脂肪链醇，地塞米松和His-Gly-Glu的缀合物，其制备，纳米结构及应用
CN104371009A (zh) * 2014-06-24 2015-02-25 上海市计划生育科学研究所 GnRH多肽-甲氨蝶呤偶联物、其制备方法及用途
CN108136038A (zh) * 2015-11-25 2018-06-08 乐高化学生物科学股份有限公司 包含肽基团的缀合物及其相关方法
WO2018208125A1 (ko) * 2017-05-11 2018-11-15 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899088A (zh) * 2009-05-26 2010-12-01 首都医科大学 饱和脂肪链酸His-Gly-AA三肽酰胺及其合成方法和应用
CN104211761A (zh) * 2013-06-05 2014-12-17 首都医科大学 饱和脂肪链醇，地塞米松和His-Gly-Glu的缀合物，其制备，纳米结构及应用
CN104371009A (zh) * 2014-06-24 2015-02-25 上海市计划生育科学研究所 GnRH多肽-甲氨蝶呤偶联物、其制备方法及用途
CN108136038A (zh) * 2015-11-25 2018-06-08 乐高化学生物科学股份有限公司 包含肽基团的缀合物及其相关方法
WO2018208125A1 (ko) * 2017-05-11 2018-11-15 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHAO WANG等: "The synthesis and immunosuppressive activities of steroid–urotoxin linkers", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
SUMIT MAJUMDAR等: "MTX-cIBR Conjugate for Targeting Methotrexate to Leukocytes: Conjugate Stability and in vivo Efficacy in Suppressing Rheumatoid Arthritis", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *
吴学萍等: "短肽修饰的甲氨蝶呤的制备及细胞毒性作用", 《中国医院药学杂志》 *
周雅梅等: "肽修饰的甲氨蝶呤体外抗肿瘤作用初步研究", 《药学学报》 *
张贤甫等: "尿毒素三肽和氢化可的松协同延长小鼠异位移植心肌的存活时间", 《北京医科大学学报》 *
王超等: "甾体-多肽缀合激素的合成及免疫抑制活性", 《药学学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094320A (zh) * 2019-06-18 2020-12-18 首都医科大学 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用
CN112094320B (zh) * 2019-06-18 2022-08-02 首都医科大学 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用

Also Published As

Publication number Publication date
CN112094321B (zh) 2022-04-22

Similar Documents

Publication Publication Date Title
CN102215688A (zh) 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
CN113087665B (zh) 一种促进细胞运动的化合物、药物组合物及其制备和应用
CN112094321B (zh) His-Gly-Glu修饰的甲氨蝶呤,其合成,抗转移活性和应用
CN109081801A (zh) 酸性氨基酸修饰的吲哚乙醇衍生物,其合成，活性和应用
CN110152013B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
CN112094317B (zh) His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用
CN111803484B (zh) 奥替溴铵在制备抗肿瘤药物中的应用
CN112300246B (zh) 天冬酰茶氨酸rgds修饰的5-氟尿嘧啶,其合成,活性和应用
CN110418653B (zh) 一种果胶-阿霉素轭合物及其制备方法和用途
CN110551121B (zh) 谷氨酰胺酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用
CN112110987B (zh) 天冬胺酰茶氨酸苯丙氨酸修饰的5-氟尿嘧啶,其合成,活性和应用
CN112390854B (zh) 茶氨酸与rgds共同修饰的5-氟尿嘧啶,其合成,活性和应用
CN112300244B (zh) 茶氨酸单独及与rgds共同修饰的5-氟尿嘧啶,其合成,活性和应用
CN112094319B (zh) Glu-Asp-Gly修饰的甲氨蝶呤,其合成,抗转移活性和应用
CN109134595B (zh) 茶氨酰氨基酸苄酯修饰的姜黄素，其合成，活性和应用
CN112300245B (zh) Rgds和茶氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用
CN112010811B (zh) 茶氨酸与苯丙氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用
CN112094320B (zh) His-Gly-Glu修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用
CN112898376B (zh) 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK,其制备,抗肿瘤活性和应用
CN108948137A (zh) 3s-吲哚乙基-6s-极性氨基酸修饰的哌嗪-2,5-二酮，其合成，活性和应用
CN108929320A (zh) 3r-吲哚甲基-6r-恶唑烷酮修饰的哌嗪-2,5-二酮，其合成，活性和应用
CN112979750B (zh) 二氧六环修饰的四氢咔啉-3-甲酰-The-EDG、其制备、抗转移活性和应用
CN110551120B (zh) 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用
CN111793115A (zh) 二羟甲基四氢咔啉-3-甲酰-The-EDG，其合成，活性和应用
CN116549499A (zh) 商陆果发酵液提取物有效部位在制备抗肿瘤药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220422